It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version.
We would like to change the Dr. Jerzy Pieczykolan’ affiliation on Page 1 of paper [1] from:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com.
to the correct version, as follows:
Drug Discovery Department, Adamed Group, Czosnow 05-152, Poland; jerzy.pieczykolan@adamed.com.pl.
And add the following affiliation as the current address of Dr. Jerzy Pieczykolan:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com.
This correction does not cause any changes to results and conclusions in the original published paper.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Serwotka-Suszczak, A.M.; Sochaj-Gregorczyk, A.M.; Pieczykolan, J.; Krowarsch, D.; Jelen, F.; Otlewski, J. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).